The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

Let's consider two corporations that could help you do better than average in the next decade: Eli Lilly (NYSE: LLY) and ...

As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Many of the best growth stocks in the world are based out of the U.S. This is the land of both opportunity and innovation.

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

Thai healthcare solutions company Zuellig Pharma has announced that Mounjaro (tirzepatide), Eli Lilly’s (NYSE: LLY) ...

Zuellig Pharma introduces Eli Lilly’s innovative obesity and diabetes medicine, Mounjaro in Thailand: Bangkok, Thailand Thursday, May 29, 2025, 11:00 Hrs [IST] Zuellig Pharma, a ...